Pfizer said it will wring another $500 million from legacy operating expenses, with cuts to its sales, R&D budgets bringing the total savings to $4 billion.
MSLs rejoice, overtaking sales reps as pharma’s prime information conveyors
Pfizer slashed the guidance for revenues of Paxlovid by $7 billion, which includes a $4.2 billion non-cash revenue reversal for the return of the nearly 8 million treatment courses from the U.S. government inventory.
Eversana debuts ‘operating system’ for targeting HCPs, patients